Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $14.00.

KLRS has been the topic of several analyst reports. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Chardan Capital initiated coverage on shares of Kalaris Therapeutics in a research note on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Finally, Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th.

Kalaris Therapeutics Trading Up 1.4%

Shares of NASDAQ KLRS opened at $9.82 on Friday. The stock has a market capitalization of $183.63 million, a price-to-earnings ratio of -2.60 and a beta of -0.13. Kalaris Therapeutics has a 12-month low of $2.14 and a 12-month high of $12.90. The firm’s 50-day moving average price is $9.36 and its 200-day moving average price is $6.94.

Insider Activity

In related news, Director Srinivas Akkaraju acquired 479,847 shares of the stock in a transaction on Thursday, December 18th. The stock was bought at an average cost of $10.42 per share, with a total value of $5,000,005.74. Following the transaction, the director directly owned 1,979,847 shares in the company, valued at approximately $20,630,005.74. This represents a 31.99% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 74.99% of the company’s stock.

Hedge Funds Weigh In On Kalaris Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp grew its stake in shares of Kalaris Therapeutics by 12.4% during the fourth quarter. State Street Corp now owns 25,410 shares of the company’s stock worth $214,000 after acquiring an additional 2,800 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new stake in Kalaris Therapeutics in the 4th quarter worth approximately $34,000. Barclays PLC purchased a new position in Kalaris Therapeutics in the fourth quarter valued at $51,000. Johnson Financial Group Inc. purchased a new position in Kalaris Therapeutics during the third quarter valued at $58,000. Finally, Keel Point LLC purchased a new stake in Kalaris Therapeutics during the 4th quarter worth approximately $86,000. 66.05% of the stock is currently owned by institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.